HealthDay on MSN17h
ACR: Inebilizumab Reduces Risk for Flares in IgG4-Related DiseaseFor patients with immunoglobulin G (IgG)4-related disease, inebilizumab reduces the risk for flares and increases the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback